{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:26:41Z","timestamp":1773710801632,"version":"3.50.1"},"reference-count":99,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the last decade, we have witnessed dramatic improvements in the diagnosis, workup, management, and monitoring of patients with hereditary transthyretin amyloidosis (ATTRv). Updated imaging techniques (e.g., 99mTc-PYP scan) are increasingly being used in place of tissue biopsies for confirmation of disease. Novel treatments now include antisense oligonucleotide and RNA interference drugs, whereas new applications such as CRISPR and amyloid antibodies are being studied for potential use in the future. These treatments have dramatically improved quality of life and increased survival in patients with ATTRv. Despite these breakthroughs, many challenges remain. Some of these challenges include early recognition and diagnosis of ATTRv, monitoring and initiation of treatment in asymptomatic or paucisymptomatic carriers, adequate treatment in people with mixed phenotype (i.e., cardiac and neurological), and the emergence of new phenotypes in people living longer with the disease (i.e., central nervous system and ocular complications). Research in those areas of deficit is ongoing, and in the future, we may have preventive therapies, better biomarkers, more efficient therapies for organs that we cannot currently target, and enhanced diagnostic techniques with the help of novel imaging techniques and artificial intelligence. In this review, we will summarize the current knowledge about polyneuropathy related to ATTRv and its management, discuss methods to improve early diagnosis and monitoring, and discuss emerging trends.<\/jats:p>","DOI":"10.1055\/s-0044-1791519","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T23:43:47Z","timestamp":1729035827000},"page":"075-087","source":"Crossref","is-referenced-by-count":3,"title":["Hereditary Transthyretin Amyloidosis Polyneuropathy"],"prefix":"10.1055","volume":"45","author":[{"given":"Taha","family":"Qarni","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orly","family":"Moshe-Lilie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Boston University, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle C.","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"M S Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"ref2","doi-asserted-by":"crossref","first-page":"6796","DOI":"10.1016\/S0021-9258(19)42128-5","article-title":"The amino acid sequence of human plasma prealbumin","volume":"249","author":"Y Kanda","year":"1974","journal-title":"J Biol Chem"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0065-3233(08)60321-6","article-title":"Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid","volume":"50","author":"J W Kelly","year":"1997","journal-title":"Adv Protein Chem"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","article-title":"Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness","volume":"27","author":"J N Nativi-Nicolau","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/CPJ.0000000000000640","article-title":"Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis","volume":"9","author":"C Karam","year":"2019","journal-title":"Neurol Clin Pract"},{"issue":"03","key":"ref6","first-page":"408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"C Andrade","year":"1952","journal-title":"Brain"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"M D Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"D Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"ref9","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"J L Berk","year":"2013","journal-title":"JAMA"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"T Coelho","year":"2012","journal-title":"Neurology"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"H H Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13506129.2017.1292903","article-title":"Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review","volume":"24","author":"H Schmidt","year":"2017","journal-title":"Amyloid"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis","volume":"93","author":"A Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"S 01","key":"ref14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/13506129.2012.673184","article-title":"Clinical features of TTR-FAP in Portugal","volume":"19","author":"I Concei\u00e7\u00e3o","year":"2012","journal-title":"Amyloid"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1136\/jmg.40.11.e120","article-title":"Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families","volume":"40","author":"V Plant\u00e9-Bordeneuve","year":"2003","journal-title":"J Med Genet"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"U Hellman","year":"2008","journal-title":"Amyloid"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"D R Jacobson","year":"1997","journal-title":"N Engl J Med"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"C A Obi","year":"2022","journal-title":"Methodist DeBakey Cardiovasc J"},{"issue":"15","key":"ref19","doi-asserted-by":"crossref","first-page":"e028973","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older Black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study","volume":"12","author":"A Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1468-1331.2008.02429.x","article-title":"Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families","volume":"16","author":"M AC Saporta","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","article-title":"Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy","volume":"14","author":"L Poli","year":"2023","journal-title":"Front Neurol"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12883-021-02094-y","article-title":"Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis","volume":"21","author":"X Lin","year":"2021","journal-title":"BMC Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"900313","DOI":"10.3389\/fcvm.2022.900313","article-title":"Clinical profile and prognosis of hereditary transthyretin amyloid cardiomyopathy: a single-center study in South China","volume":"9","author":"S Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"A S Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"S 01","key":"ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10286-019-00630-y","article-title":"Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review","volume":"29","author":"A Gonzalez-Duarte","year":"2019","journal-title":"Clin Auton Res"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-2836(74)90291-5","article-title":"Structure of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding","volume":"88","author":"C CF Blake","year":"1974","journal-title":"J Mol Biol"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/humu.1132","article-title":"Transthyretin mutations in hyperthyroxinemia and amyloid diseases","volume":"17","author":"M JM Saraiva","year":"2001","journal-title":"Hum Mutat"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0006-291X(85)80027-9","article-title":"High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain","volume":"127","author":"P W Dickson","year":"1985","journal-title":"Biochem Biophys Res Commun"},{"issue":"21","key":"ref29","doi-asserted-by":"crossref","first-page":"11793","DOI":"10.1016\/S0021-9258(17)39100-7","article-title":"Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat","volume":"260","author":"D R Soprano","year":"1985","journal-title":"J Biol Chem"},{"key":"ref30","first-page":"493","volume-title":"Sural nerve biopsy in familial amyloidotic polyneuropathy: a morphological and morphometric polyneuropathy","author":"A Guimaraes","year":"1990"},{"issue":"08","key":"ref31","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"L Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/ajkd.1998.v31.pm9631837","article-title":"Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits","volume":"31","author":"L Lobato","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"e13354","DOI":"10.1111\/nmo.13354","article-title":"Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis","volume":"30","author":"J Wixner","year":"2018","journal-title":"Neurogastroenterol Motil"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1212\/WNL.32.12.1364","article-title":"Gastrointestinal amyloid deposition in familial amyloid polyneuropathy","volume":"32","author":"S I Ikeda","year":"1982","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cca.2008.07.033","article-title":"Impact of serotonin transporter and catechol-O-methyl transferase genes polymorphism on gastrointestinal dysfunction in Swedish and Japanese familial amyloidotic polyneuropathy patients","volume":"398","author":"K Obayashi","year":"2008","journal-title":"Clin Chim Acta"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/00365529609031629","article-title":"Endocrine cells in rectal biopsy specimens from patients with familial amyloidotic polyneuropathy","volume":"31","author":"M El-Salhy","year":"1996","journal-title":"Scand J Gastroenterol"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-2796.1999.00484.x","article-title":"Colonic endocrine cells in patients with familial amyloidotic polyneuropathy","volume":"245","author":"I Anan","year":"1999","journal-title":"J Intern Med"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1471-4159.2006.04210.x","article-title":"Transthyretin oligomers induce calcium influx via voltage-gated calcium channels","volume":"100","author":"X Hou","year":"2007","journal-title":"J Neurochem"},{"issue":"S 01","key":"ref39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/13506129.2003.12088561","article-title":"Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration","volume":"10","author":"G Said","year":"2003","journal-title":"Amyloid"},{"issue":"21","key":"ref40","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","article-title":"Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy","volume":"87","author":"H Koike","year":"2016","journal-title":"Neurology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/brain\/awu344","article-title":"In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography","volume":"138","author":"J Kollmer","year":"2015","journal-title":"Brain"},{"issue":"02","key":"ref42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"E Ihse","year":"2008","journal-title":"J Pathol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"H Koike","year":"2009","journal-title":"J Neurol Sci"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","article-title":"Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy","volume":"63","author":"H Koike","year":"2004","journal-title":"Neurology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/brain\/113.4.903","article-title":"Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system","volume":"113","author":"G Sobue","year":"1990","journal-title":"Brain"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1248\/bpb.b17-01021","article-title":"Characterization of non-amyloidogenic G101S transthyretin","volume":"41","author":"Y Wakita","year":"2018","journal-title":"Biol Pharm Bull"},{"issue":"17","key":"ref47","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"M Miller","year":"2018","journal-title":"J Med Chem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"44709","DOI":"10.1038\/srep44709","article-title":"Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation","volume":"7","author":"R Sant'Anna","year":"2017","journal-title":"Sci Rep"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/13506120208995246","article-title":"Identification of a novel transthyretin Thr59Lys\/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis","volume":"9","author":"A Lim","year":"2002","journal-title":"Amyloid"},{"issue":"06","key":"ref50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy","volume":"33","author":"L S Hornstrup","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"01","key":"ref51","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"17","author":"A Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"05","key":"ref52","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy associated with systemic amyloidosis","volume":"39","author":"M Kaku","year":"2019","journal-title":"Semin Neurol"},{"issue":"21","key":"ref53","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"M A Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"H Koike","year":"2002","journal-title":"Arch Neurol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2019.05.030","article-title":"Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: characterization of Brazilian subjects from the THAOS registry","volume":"403","author":"M V Pinto","year":"2019","journal-title":"J Neurol Sci"},{"issue":"09","key":"ref56","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"P T Sattianayagam","year":"2012","journal-title":"Eur Heart J"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13506129.2022.2046557","article-title":"Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays","volume":"29","author":"M C Kaku","year":"2022","journal-title":"Amyloid"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s10038-020-0749-3","article-title":"Presence of val30Met and val122ile mutations in a patient with hereditary amyloidosis","volume":"65","author":"J A da Silva-Batista","year":"2020","journal-title":"J Hum Genet"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/13506129.2022.2135988","article-title":"An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis","volume":"30","author":"T Prokaeva","year":"2023","journal-title":"Amyloid"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00401-022-02501-9","article-title":"Neuropathology of central nervous system involvement in TTR amyloidosis","volume":"145","author":"R Taipa","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"L F Maia","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/13506129.2019.1672649","article-title":"Misdiagnosis of hATTR amyloidosis: a single US site experience","volume":"27","author":"C Karam","year":"2020","journal-title":"Amyloid"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13023-020-01623-1","article-title":"The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis","volume":"16","author":"M Vera-Llonch","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/TCRM.S185677","article-title":"Diagnosis and screening of patients with hereditary transthyretin amyloidosis (Hattr): current strategies and guidelines","volume":"16","author":"M D Benson","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.28026","article-title":"Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts","volume":"69","author":"C Karam","year":"2024","journal-title":"Muscle Nerve"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"D Adams","year":"2023","journal-title":"Amyloid"},{"issue":"15","key":"ref67","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"T Coelho","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2023.2232520","article-title":"Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study","volume":"31","author":"S Ticau","year":"2024","journal-title":"Amyloid"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/13506129.2024.2313218","article-title":"Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice","volume":"31","author":"A S Carroll","year":"2024","journal-title":"Amyloid"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1007\/s00415-020-09899-w","article-title":"Screening for genetic mutations in patients with neuropathy without definite etiology is useful","volume":"267","author":"B Vogt","year":"2020","journal-title":"J Neurol"},{"key":"ref71","volume-title":"Hereditary transthyretin amyloidosis","author":"Y Sekijima","year":"1993"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jmoldx.2013.08.001","article-title":"Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life","volume":"16","author":"H V Reddi","year":"2014","journal-title":"J Mol Diagn"},{"issue":"S 01","key":"ref73","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"L Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"P Lozeron","year":"2018","journal-title":"Neurology"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00415-020-10127-8","article-title":"Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers","volume":"268","author":"A Salvalaggio","year":"2021","journal-title":"J Neurol"},{"issue":"11","key":"ref76","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1007\/s00330-022-08748-w","article-title":"3-T MR neurography of lumbo-sacral plexus in hereditary transthyretin-related amyloidosis with polyneuropathy","volume":"32","author":"J Hodel","year":"2022","journal-title":"Eur Radiol"},{"issue":"10","key":"ref77","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1007\/s00415-023-11813-z","article-title":"Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy","volume":"270","author":"R Gasparotti","year":"2023","journal-title":"J Neurol"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"G J Ebenezer","year":"2017","journal-title":"Ann Neurol"},{"issue":"11","key":"ref79","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3390\/brainsci10110780","article-title":"hATTR pathology: nerve biopsy results from Italian referral centers","volume":"10","author":"M Luigetti","year":"2020","journal-title":"Brain Sci"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506129.2017.1313222","article-title":"Amyloid detection in the transverse carpal ligament of patients with hereditary ATTR V30M amyloidosis and carpal tunnel syndrome","volume":"24","author":"R Sam\u00f5es","year":"2017","journal-title":"Amyloid"},{"issue":"02","key":"ref81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10072-016-2760-1","article-title":"Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy","volume":"38","author":"F de Paula Eduardo","year":"2017","journal-title":"Neurol Sci"},{"issue":"24","key":"ref82","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"C C Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-020-01565-8","article-title":"Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis","volume":"15","author":"H Paulsson Rokke","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"ref84","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"J D Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00392-020-01771-1","article-title":"Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study","volume":"110","author":"G Chatzantonis","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jclinpath-2014-202722","article-title":"A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue","volume":"68","author":"J A Gilbertson","year":"2015","journal-title":"J Clin Pathol"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/archneurol.2010.261","article-title":"Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue","volume":"68","author":"C J Klein","year":"2011","journal-title":"Arch Neurol"},{"issue":"08","key":"ref88","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"A Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"116424","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS\u202f+\u202f7","volume":"405","author":"P JB Dyck","year":"2019","journal-title":"J Neurol Sci"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123","author":"D Adams","year":"2000","journal-title":"Brain"},{"issue":"09","key":"ref91","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","article-title":"Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy","volume":"78","author":"T Yamashita","year":"2012","journal-title":"Neurology"},{"issue":"03","key":"ref92","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"A Carvalho","year":"2015","journal-title":"Liver Transpl"},{"issue":"17","key":"ref93","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"M S Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"01","key":"ref94","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"N R Dasgupta","year":"2020","journal-title":"Amyloid"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"T Coelho","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"01","key":"ref96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-024-03198-7","article-title":"Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study","volume":"19","author":"T N Qarni","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"02","key":"ref97","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"J D Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","article-title":"Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study","volume":"26","author":"J Gamez","year":"2019","journal-title":"Amyloid"},{"issue":"48","key":"ref99","doi-asserted-by":"crossref","first-page":"25096","DOI":"10.1074\/jbc.M116.738138","article-title":"Novel antibody for the treatment of transthyretin amyloidosis","volume":"291","author":"A Hosoi","year":"2016","journal-title":"J Biol Chem"}],"container-title":["Seminars in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1791519.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T23:31:14Z","timestamp":1737156674000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1791519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":99,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1791519","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0271-8235","1098-9021"],"issn-type":[{"value":"0271-8235","type":"print"},{"value":"1098-9021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}